Treatment of acute deep vein thrombosis in spinal cord injured patients with enoxaparin: A cost analysis

Journal of Spinal Cord Medicine

Volumn 21, Issue 3, 1998, Pages 205-210

  Tomaio, Alfred ^a   Kirshblum, Steven C ^a,b   O'Connor, Kevin C ^a,b   Johnston, Mark ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b KESSLER INSTITUTE FOR REHABILITATION   (United States)

Author keywords

Deep vein thrombosis; Enoxaparin; Spinal cord injury

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN;

ADULT; ARTICLE; COMPARATIVE STUDY; COST; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PILOT STUDY; REHABILITATION CENTER; RETROSPECTIVE STUDY; SPINAL CORD INJURY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOPHLEBITIS;

ADULT; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; REHABILITATION CENTERS; RETROSPECTIVE STUDIES; SPINAL CORD INJURIES; THROMBOPHLEBITIS;

EID: 0032106692     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.1998.11719528     Document Type: Article

References (30)

1. Waring WP, Karunas RS. Acute spinal cord injuries and the incidence of clinically occurring thromboembolic disease. Paraplegia 1991;29:8-16.
2. Merli G, et al. Etiology, incidence, and prevention of deep venous thrombosis in acute spinal cord injury. Arch Phys Med Rehabil 1993;74:199-205.
3. Weingarden SI. Deep venous thrombosis in spinal cord injury. Chest 1992;102(suppl):636S-39S.
4. Ragnarsson KT, Hall KM, Wilmot CB, Carter RE. Management of pulmonary, cardiovascular, and metabolic conditions after spinal cord injury. In Stover SL, DeLisa JA, Whiteneck GG, eds. Spinal cord injury: clinical outcomes from the model systems. Gaithersburg, MD; Aspen Publishers, 1995;79-99.
5. Merli GI, Herbison GJ, Ditunno JF, et al. Deep vein thrombosis. Prophylaxis in acute spinal cord injured patients. Arch Phys Med Rehabil 1988;69:661-64.
6. Myllynen P, Kummonen M, Rokkannen P, et al. Deep venous thrombosis and pulmonary embolism in patients with spinal cord injury: comparison with non-paralyzed patients immobilized due to spinal fractures. J Trauma 1985;25:541-43.
7. Monreal M, Martorell A, Callejas JM, et al. Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. J Int Med 1993;233:233-38.
8. Clark S. Current issues in management of thrombosis. Lancet 1995;346:113-14.
9. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
10. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-28.
11. Weitz JI. Low molecular weight heparin. N Engl J Med 1997;337:668-98.
12. The Physicians Desk Reference 1996;50:2020.
13. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995;49:388-10.
14. Warkentin TE, Levine MN, Hirsch J., et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-35.
15. Monreal M, Lafoz E, Olive A, del Rio L, Verdia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11.
16. Lindmarker P, Holmstrom M, Grenqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
17. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in the proximal deep vein thrombosis. Lancet 1992;339:441-45.
18. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after knee or hip implantation. N Engl J Med 1993;329:1370-76.
19. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular weight heparin compared to continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Int Med 1993;153:1541-46.
20. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-81.
21. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-87.
22. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecularweight heparin versus intravenous heparin: an economic perspective. Arch Int Med 1997;157:289-94.
23. The Columbia Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
24. White J, et al. Diagnosis of deep vein thrombosis using duplex ultrasound. Ann Int Med 1989;11:1297-1304.
25. Killewich LA, Bedford GR, Beach KW, Strandness DE. Diagnosis of deep vein thrombosis. A prospective study comparing duplex scanning to contrast venography. Circulation 1989;79:810-14.
26. Green D, Chen D, Chiel J, et al. Prevention of thromboembolism in spinal cord injury: the role of low molecular weight heparin. Arch Phys Med Rehabil 1994;75:290-92.
27. Harris S, Chen D, Green D. Enoxaparin for thromboembolism prophylaxis in spinal injury. Am J Phys Med Rehabil, 1996;75:326-27.
28. Green D, Lee M, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low molecular weight heparin. Ann Intern Med 1990;113:571-74.
29. Green D, Biddle A, Fahey V, et al. Prevention of thromboembolism in spinal cord injury. Consortium for Spinal Cord Medicine, 1997.
30. Litin SC, Gastineau DA. Current concepts in anticoagulant therapy. Mayo Clin Proc 1995;70:266-67.